Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986259 in Healthy Participants
NCT04008992Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2019
- Primary completion
- Jan 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of FA relaxin in heart failure (HF) (13 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events (AEs) up to 7 weeks, Incidence of Serious Adverse Events (SAEs) up to 7 weeks and 5 more. Started Jun 2019; status: completed.
02
Drugs
FA relaxin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04008992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008992.